Epigenetic regulation of gap junctional intercellular communication: More than a way to keep cells quiet?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1795, Issue 1, 2009, Pages 53-61

  Vinken, Mathieu ^a   De Rop, Evelien ^a   Decrock, Elke ^b   De Vuyst, Elke ^b   Leybaert, Luc ^b   Vanhaecke, Tamara ^a   Rogiers, Vera ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Connexin; DNA methylation; Gap junction; Histone acetylation; MicroRNA

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; GAP JUNCTION PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; TRANSCRIPTION FACTOR; TRICHOSTATIN A; VORINOSTAT;

ACETYLATION; CELL COMMUNICATION; DNA METHYLATION; EPIGENETICS; GAP JUNCTION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REGULATORY SEQUENCE; REVIEW;

ANIMALS; CELL COMMUNICATION; CELL PHYSIOLOGICAL PHENOMENA; CONNEXINS; DNA METHYLATION; EPIGENESIS, GENETIC; GAP JUNCTIONS; HISTONES; HOMEOSTASIS; HUMANS; MICRORNAS; MODELS, BIOLOGICAL;

PYRONIA TITHONUS;

EID: 58049181324     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2008.08.002     Document Type: Review

References (119)

1. Trosko J.E., and Ruch R.J. Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr. Drug Targets 3 (2002) 465-482
2. Vinken M., Vanhaecke T., Papeleu P., Snykers S., Henkens T., and Rogiers V. Connexins and their channels in cell growth and cell death. Cell. Signal. 18 (2006) 592-600
3. Vinken M., Peggy P., Vera R., and Tamara V. Histone deacetylase inhibitors as potent modulators of cellular contacts. Curr. Drug Targets 7 (2006) 773-787
4. Vinken M., Henkens T., De Rop E., Fraczek J., Vanhaecke T., and Rogiers V. Biology and pathobiology of gap junctional channels in hepatocytes. Hepatology 47 (2008) 1077-1088
5. Oyamada M., Oyamada Y., and Takamatsu T. Regulation of connexin expression. Biochim. Biophys. Acta 1719 (2005) 6-23
6. Lafon-Hughes L., Di Tomaso M.V., Méndez-Acuña L., and Martínez-López W. Chromatin-remodelling mechanisms in cancer. Mutat. Res. 658 (2008) 191-214
7. Maekawa M., and Watanabe Y. Epigenetics: relations to disease and laboratory findings. Curr. Med. Chem. 14 (2007) 2642-2653
8. Leithe E., Sirnes S., Omori Y., and Rivedal E. Downregulation of gap junctions in cancer cells. Crit. Rev. Oncog. 12 (2006) 225-256
9. Pointis G., Fiorini C., Gilleron J., Carette D., and Segretain D. Connexins as precocious markers and molecular targets for chemical and pharmacological agents in carcinogenesis. Curr. Med. Chem. 14 (2007) 2288-2303
10. Czyz J. The stage-specific function of gap junctions during tumourigenesis. Cell. Mol. Biol. Lett. 13 (2008) 92-102
11. Shestopalov V.I., and Panchin Y. Pannexins and gap junction protein diversity. Cell. Mol. Life Sci. 65 (2008) 376-394
12. Söhl G., and Willecke K. Gap junctions and the connexin protein family. Cardiovasc. Res. 62 (2004) 228-232
13. Martin P.E., and Evans W.H. Incorporation of connexins into plasma membranes and gap junctions. Cardiovasc. Res. 62 (2004) 378-387
14. Cottrell G.T., and Burt J.M. Functional consequences of heterogeneous gap junction channel formation and its influence in health and disease. Biochim. Biophys. Acta 1711 (2005) 126-141
15. Laird D.W. Life cycle of connexins in health and disease. Biochem. J. 394 (2006) 527-543
16. Richard G. Connexins: a connection with the skin. Exp. Dermatol. 9 (2000) 77-96
17. Sosinsky G.E., and Nicholson B.J. Structural organization of gap junction channels. Biochim. Biophys. Acta 1711 (2005) 99-125
18. Alexander D.B., and Goldberg G.S. Transfer of biologically important molecules between cells through gap junction channels. Curr. Med. Chem. 10 (2003) 2045-2058
19. Kardami E., Dang X., Iacobas D.A., Nickel B.E., Jeyaraman M., Srisakuldee W., Makazan J., Tanguy S., and Spray D.C. The role of connexins in controlling cell growth and gene expression. Prog. Biophys. Mol. Biol. 94 (2007) 245-264
20. Krysko D.V., Leybaert L., Vandenabeele P., and D'Herde K. Gap junctions and the propagation of cell survival and cell death signals. Apoptosis 10 (2005) 459-469
21. Michon L., Nlend Nlend R., Bavamian S., Bischoff L., Boucard N., Caille D., Cancela J., Charollais A., Charpantier E., Klee P., Peyrou M., Populaire C., Zulianello L., and Meda P. Involvement of gap junctional communication in secretion. Biochim. Biophys. Acta 1719 (2005) 82-101
22. Evans W.H., De Vuyst E., and Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem. J. 397 (2006) 1-14
23. Jiang J.X., and Gu S. Gap junction- and hemichannel-independent actions of connexins. Biochim. Biophys. Acta 1711 (2005) 208-214
24. Rodríguez-Sinovas A., Cabestrero A., López D., Torre I., Morente M., Abellán A., Miró E., Ruiz-Meana M., and García-Dorado D. The modulatory effects of connexin 43 on cell death/survival beyond cell coupling. Prog. Biophys. Mol. Biol. 94 (2007) 219-232
25. Laird D.W. Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim. Biophys. Acta 1711 (2005) 172-182
26. Solan J.L., and Lampe P.D. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim. Biophys. Acta 1711 (2005) 154-163
27. Lampe P.D., and Lau A.F. The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell Biol. 36 (2004) 1171-1186
28. Söhl G., and Willecke K. An update on connexin genes and their nomenclature in mouse and man. Cell Commun. Adhes. 10 (2003) 173-180
29. Saez J.C., Berthoud V.M., Branes M.C., Martinez A.D., and Beyer E.C. Plasma membrane channels formed by connexins: their regulation and functions. Physiol. Rev. 83 (2003) 1359-1400
30. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
31. Costa F.F. Non-coding RNAs, epigenetics and complexity. Gene 410 (2008) 9-17
32. Grønbaek K., Hother C., and Jones P.A. Epigenetic changes in cancer. APMIS 115 (2007) 1039-1059
33. Reamon-Buettner S.M., Mutschler V., and Borlak J. The next innovation cycle in toxicogenomics: environmental epigenetics. Mutat. Res. 659 (2008) 158-165
34. Saetrom P., Snøve Jr. O., and Rossi J.J. Epigenetics and microRNAs. Pediatr. Res. 61 (2007) 17R-23R
35. Smith L.T., Otterson G.A., and Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23 (2007) 449-456
36. Yang N., Coukos G., and Zhang L. MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int. J. Cancer 122 (2008) 963-968
37. Mulero-Navarro S., and Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 68 (2008) 1-11
38. Reamon-Buettner S.M., and Borlak J. A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation. Reprod. Toxicol. 24 (2007) 20-30
39. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol. Sci. 100 (2007) 7-23
40. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
41. Li B., Carey M., and Workman J.L. The role of chromatin during transcription. Cell 128 (2007) 707-719
42. Ducasse M., and Brown M.A. Epigenetic aberrations and cancer. Mol. Cancer 5 (2006) 60
43. Yang X.J., and Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26 (2007) 5310-5318
44. Voelter-Mahlknecht S., Ho A.D., and Mahlknecht U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol. Med. 16 (2005) 589-598
45. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3 (2008) 28-37
46. Saunders L.R., and Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26 (2007) 5489-5504
47. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2 (2005) S4-S11
48. Costello J.F., and Plass C. Methylation matters. J. Med. Genet. 38 (2001) 285-303
49. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3 (2003) 253-266
50. Turek-Plewa J., and Jagodziński P.P. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell. Mol. Biol. Lett. 10 (2005) 631-647
51. Siedlecki P., and Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim. Pol. 53 (2006) 245-256
52. Szyf M. Targeting DNA methylation in cancer. Ageing Res. Rev. 2 (2003) 299-328
53. Yasui D.H., Peddada S., Bieda M.C., Vallero R.O., Hogart A., Nagarajan R.P., Thatcher K.N., Farnham P.J., and Lasalle J.M. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. USA 104 (2007) 19416-19421
54. Cameron E.E., Bachman K.E., Myöhänen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
55. Peedicayil J. Epigenetic therapy: a new development in pharmacology. Indian J. Med. Res. 123 (2006) 17-24
56. Zhu W.G., and Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents 3 (2003) 187-199
57. Szymanski M., Barciszewska M.Z., Erdmann V.A., and Barciszewski J. A new frontier for molecular medicine: noncoding RNAs. Biochim. Biophys. Acta 1756 (2005) 65-75
58. Costa F.F. Non-coding RNAs: lost in translation?. Gene 386 (2007) 1-10
59. Chu C.Y., and Rana T.M. Small RNAs: regulators and guardians of the genome. J. Cell. Physiol. 213 (2007) 412-419
60. Filipowicz W., Bhattacharyya S.N., and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight. Nat. Rev. Genet. 9 (2008) 102-114
61. Collins R.E., and Cheng X. Structural and biochemical advances in mammalian RNAi. J. Cell. Biochem. 99 (2006) 1251-1266
62. Zaratiegui M., Irvine D.V., and Martienssen R.A. Noncoding RNAs and gene silencing. Cell 128 (2007) 763-776
63. Zilberman D., Cao X., and Jacobsen S.E. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation. Science 299 (2003) 716-719
64. Kim D.H., Villeneuve L.M., Morris K.V., and Rossi J.J. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat. Struct. Mol. Biol. 13 (2006) 793-797
65. Rajewsky N. MicroRNA target predictions in animals. Nat. Genet. 38 (2006) S8-S13
66. Tuddenham L., Wheeler G., Ntounia-Fousara S., Waters J., Hajihosseini M.K., Clark I., and Dalmay T. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 580 (2006) 4214-4217
67. Lujambio A., and Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6 (2007) 1455-1459
68. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., and Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006) 435-443
69. Ammerpohl O., Thormeyer D., Khan Z., Appelskog I.B., Gojkovic Z., Almqvist P.M., and Ekström T.J. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem. Biophys. Res. Commun. 324 (2004) 8-14
70. Ammerpohl O., Trauzold A., Schniewind B., Griep U., Pilarsky C., Grutzmann R., Saeger H.D., Janssen O., Sipos B., Kloppel G., and Kalthoff H. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br. J. Cancer 96 (2007) 73-81
71. Asklund T., Appelskog I.B., Ammerpohl O., Ekström T.J., and Almqvist P.M. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur. J. Cancer 40 (2004) 1073-1081
72. Hernandez M., Shao Q., Yang X.J., Luh S.P., Kandouz M., Batist G., Laird D.W., and Alaoui-Jamali M.A. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate 66 (2006) 1151-1161
73. Khan Z., Akhtar M., Asklund T., Juliusson B., Almqvist P.M., and Ekström T.J. HDAC inhibition amplifies gap junction communication in neural progenitors: potential for cell-mediated enzyme prodrug therapy. Exp. Cell Res. 31 (2007) 2958-2967
74. Ogawa T., Hayashi T., Kyoizumi S., Ito T., Trosko J.E., and Yorioka N. Up-regulation of gap junctional intercellular communication by hexamethylene bisacetamide in cultured human peritoneal mesothelial cells. Lab. Invest. 79 (1999) 1511-1520
75. Ogawa T., Hayashi T., Yorioka N., Kyoizumi S., and Trosko J.E. Hexamethylene bisacetamide protects peritoneal mesothelial cells from glucose. Kidney Int. 60 (2001) 996-1008
76. Ogawa T., Hayashi T., Tokunou M., Nakachi K., Trosko J.E., Chang C.C., and Yorioka N. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus. Cancer Res. 65 (2005) 9771-9778
77. Vinken M., Henkens T., Vanhaecke T., Papeleu P., Geerts A., Van Rossen E., Chipman J.K., Meda P., and Rogiers V. Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes. Toxicol. Sci. 91 (2006) 484-492
78. Vinken M., Henkens T., Snykers S., Lukaszuk A., Tourwé D., Rogiers V., and Vanhaecke T. The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytes. Toxicology 236 (2007) 92-102
79. Hohl M., and Thiel G. Cell type-specific regulation of RE-1 silencing transcription factor (REST) target genes. Eur. J. Neurosci. 22 (2005) 2216-2230
80. Yamashita Y., Shimada M., Harimoto N., Tanaka S., Shirabe K., Ijima H., Nakazawa K., Fukuda J., Funatsu K., and Maehara Y. cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells. Cell Transplant. 13 (2004) 793-799
81. Martin D., Tawadros T., Meylan L., Abderrahmani A., Condorelli D.F., Waeber G., and Haefliger J.A. Critical role of the transcriptional repressor neuron-restrictive silencer factor in the specific control of connexin36 in insulin-producing cell lines. J. Biol. Chem. 278 (2003) 53082-53089
82. Martin D., Allagnat F., Chaffard G., Caille D., Fukuda M., Regazzi R., Abderrahmani A., Waeber G., Meda P., Maechler P., and Haefliger J.A. Functional significance of repressor element 1 silencing transcription factor (REST) target genes in pancreatic beta cells. Diabetologia 51 (2008) 1429-1439
83. Kapoor P., Saunders M.M., Li Z., Zhou Z., Sheaffer N., Kunze E.L., Samant R.S., Welch D.R., and Donahue H.J. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int. J. Cancer 111 (2004) 693-697
84. Samant R.S., Seraj M.J., Saunders M.M., Sakamaki T.S., Shevde L.A., Harms J.F., Leonard T.O., Goldberg S.F., Budgeon L., Meehan W.J., Winter C.R., Christensen N.D., Verderame M.F., Donahue H.J., and Welch D.R. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin. Exp. Metastasis 18 (2001) 683-693
85. Saunders M.M., Seraj M.J., Li Z., Zhou Z., Winter C.R., Welch D.R., and Donahue H.J. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res. 61 (2001) 1765-1767
86. Shevde L.A., Samant R.S., Goldberg S.F., Sikaneta T., Alessandrini A., Donahue H.J., Mauger D.T., and Welch D.R. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp. Cell Res. 273 (2002) 229-239
87. Meehan W.J., Samant R.S., Hopper J.E., Carrozza M.J., Shevde L.A., Workman J.L., Eckert K.A., Verderame M.F., and Welch D.R. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J. Biol. Chem. 279 (2004) 1562-1569
88. Zupkovitz G., Tischler J., Posch M., Sadzak I., Ramsauer K., Egger G., Grausenburger R., Schweifer N., Chiocca S., Decker T., and Seiser C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol. 26 (2006) 7913-7928
89. Leone S., Fiore M., Lauro M.G., Pino S., Cornetta T., and Cozzi R. Resveratrol and X rays affect gap junction intercellular communications in human glioblastoma cells. Mol. Carcinog. 47 (2008) 587-598
90. J.H. Kim, B.K. Lee, K.W. Lee, H.J. Lee, Resveratrol counteracts gallic acid-induced down-regulation of gap-junction intercellular communication, J. Nutr. Biochem. (in press).
91. Nielsen M., Ruch R.J., and Vang O. Resveratrol reverses tumor-promoter-induced inhibition of gap-junctional intercellular communication. Biochem. Biophys. Res. Commun. 275 (2000) 804-809
92. Upham B.L., Guzvić M., Scott J., Carbone J.M., Blaha L., Coe C., Li L.L., Rummel A.M., and Trosko J.E. Inhibition of gap junctional intercellular communication and activation of mitogen-activated protein kinase by tumor-promoting organic peroxides and protection by resveratrol. Nutr. Cancer 57 (2007) 38-47
93. Jung J.W., Cho S.D., Ahn N.S., Yang S.R., Park J.S., Jo E.H., Hwang J.W., Aruoma O.I., Lee Y.S., and Kang K.S. Effects of the histone deacetylases inhibitors sodium butyrate and trichostatin A on the inhibition of gap junctional intercellular communication by H2O2- and 12-O-tetradecanoylphorbol-13-acetate in rat liver epithelial cells. Cancer Lett. 241 (2006) 301-308
94. Chen Y., Hühn D., Knösel T., Pacyna-Gengelbach M., Deutschmann N., and Petersen I. Downregulation of connexin 26 in human lung cancer is related to promoter methylation. Int. J. Cancer 113 (2005) 14-21
95. Hirai A., Yano T., Nishikawa K., Suzuki K., Asano R., Satoh H., Hagiwara K., and Yamasaki H. Down-regulation of connexin 32 gene expression through DNA methylation in a human renal cell carcinoma cell. Am. J. Nephrol. 23 (2003) 172-177
96. Yano T., Ito F., Kobayashi K., Yonezawa Y., Suzuki K., Asano R., Hagiwara K., Nakazawa H., Toma H., and Yamasaki H. Hypermethylation of the CpG island of connexin 32, a candiate tumor suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett. 208 (2004) 137-142
97. Loncarek J., Yamasaki H., Levillain P., Milinkevitch S., and Mesnil M. The expression of the tumor suppressor gene connexin 26 is not mediated by methylation in human esophageal cancer cells. Mol. Carcinog. 36 (2003) 74-81
98. Singal R., Tu Z.J., Vanwert J.M., Ginder G.D., and Kiang D.T. Modulation of the connexin26 tumor suppressor gene expression through methylation in human mammary epithelial cell lines. Anticancer Res. 20 (2000) 59-64
99. Yi Z.C., Wang H., Zhang G.Y., and Xia B. Downregulation of connexin 43 in nasopharyngeal carcinoma cells is related to promoter methylation. Oral Oncol. 43 (2007) 898-904
100. Piechocki M.P., Burk R.D., and Ruch R.J. Regulation of connexin32 and connexin43 gene expression by DNA methylation in rat liver cells. Carcinogenesis 20 (1999) 401-406
101. Shimizu K., Onishi M., Sugata E., Sokuza Y., Mori C., Nishikawa T., Honoki K., and Tsujiuchi T. Disturbance of DNA methylation patterns in the early phase of hepatocarcinogenesis induced by a choline-deficient l-amino acid-defined diet in rats. Cancer Sci. 98 (2007) 1318-1322
102. Tsujiuchi T., Shimizu K., Itsuzaki Y., Onishi M., Sugata E., Fujii H., and Honoki K. CpG site hypermethylation of E-cadherin and connexin26 genes in hepatocellular carcinomas induced by a choline-deficient l-amino acid-defined diet in rats. Mol. Carcinog. 46 (2007) 269-274
103. Shimizu K., Shimoichi Y., Hinotsume D., Itsuzaki Y., Fujii H., Honoki K., and Tsujiuchi T. Reduced expression of the connexin26 gene and its aberrant DNA methylation in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol. Carcinog. 45 (2006) 710-714
104. Hagiwara H., Sato H., Ohde Y., Takano Y., Seki T., Ariga T., Hokaiwado N., Asamoto M., Shirai T., Nagashima Y., and Yano T. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br. J. Pharmacol. 153 (2008) 1373-1381
105. King T.J., Fukushima L.H., Donlon T.A., Hieber A.D., Shimabukuro K.A., and Bertram J.S. Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression. Carcinogenesis 21 (2000) 311-315
106. Tan L.W., Bianco T., and Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene connexin 26 in breast cancer. Carcinogenesis 23 (2002) 231-236
107. Chen J.T., Cheng Y.W., Chou M.C., Sen-Lin T., Lai W.W., Ho W.L., and Lee H. The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer. Clin. Cancer Res. 9 (2003) 4200-4204
108. Kim H.K., Lee Y.S., Sivaprasad U., Malhotra A., and Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J. Cell Biol. 174 (2006) 677-687
109. Anderson C., Catoe H., and Werner R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res. 34 (2006) 5863-5871
110. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., Zhang Y., Xu C., Bai Y., Wang H., Chen G., and Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13 (2007) 486-491
111. Itoh Y., Suzuki T., and Miyata N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 14 (2008) 529-544
112. Sahu N.K., Shilakari G., Nayak A., and Kohli D.V. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr. Pharm. Biotechnol. 8 (2007) 291-304
113. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., and Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438 (2005) 685-689
114. Qi P., Han J.X., Lu Y.Q., Wang C., and Bu F.F. Virus-encoded microRNAs: future therapeutic targets?. Cell. Mol. Immunol. 3 (2006) 411-419
115. Elaut G., Rogiers V., and Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 13 (2007) 2584-2620
116. Vanhaecke T., Papeleu P., Elaut G., and Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. 11 (2004) 1629-1643
117. Hattori Y., Fukushima M., and Maitani Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. Int. J. Oncol. 30 (2007) 1427-1439
118. Robe P.A., Jolois O., N'Guyen M., Princen F., Malgrange B., Merville M.P., and Bours V. Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int. J. Oncol. 25 (2004) 187-192
119. Germann A., Dihlmann S., Hergenhahn M., Doeberitz M.K., and Koesters R. Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin. Int. J. Cancer 106 (2003) 187-197